Pharmaceutical Products

Our pharmaceutical products and medical devices focus on patients suffering from cystic fibrosis and bronchiectasis and are available throughout Europe. For information about Aptalis products, click here.

Close
Thank you for visiting

You are now leaving the Forest Europe website. Forest Europe is not responsible for the accuracy, content, practices and standards of external sites.

Would you like to continue?

Close
Thank you for visiting

You are now leaving the Forest Europe website for a US website. This content is intended for a US audience.

Would you like to continue?

Close
Thank you for visiting

You are now leaving the Forest Europe website for a Canadian website. This content is intended for a Canadian audience.

Would you like to continue?

COLOBREATHE®
Close

What is COLOBREATHE®?

COLOBREATHE® contains the active ingredient colistimethate sodium. Colistimethate sodium is an antibiotic used in the management of chronic pulmonary infections caused by the bacterium Pseudomonas aeruginosa in patients of age 6 years and older with cystic fibrosis.

How is it taken?

COLOBREATHE is administered via the TURBOSPIN® inhaler as one capsule, twice daily. The device itself is breath-actuated when a patient breathes in through the inhaler. COLOBREATHE can be taken without medical supervision after the first dose.

Like all medicines, COLOBREATHE can have possible side effects. Always consult your doctor before taking COLOBREATHE. Always read the label.

Where can I learn more?

For UK product information, click here.

COLOMYCIN®/COLISTIN
Close

What is COLOMYCIN®?

COLOMYCIN® is an antibiotic used to treat infections caused by the bacterium Pseudomonas aeruginosa, which causes infections common in adults and children who have cystic fibrosis. COLOMYCIN can be given via intravenous injection or via nebulisation.

COLOMYCIN Injection can also be used to treat some pneumonias and infections of the bladder and kidneys.

How is it taken?

COLOMYCIN Injection is a powder that is diluted in saline solution and delivered to patients either intravenously through injection, as an infusion or via inhalation through nebulisation.

Like all medicines, COLOMYCIN can have possible side effects. Always consult your doctor before taking COLOMYCIN. Always read the label.

Where can I learn more?

Prescribing Information is variable and depends on your region; check with your local market to access the approved product information.

For UK product information about the COLOMYCIN injection, click here.

NEBUSAL®
Close

What is NEBUSAL®?

NEBUSAL®, a recognised medical device, is a CE marked 7% hypertonic saline sterile solution recommended by the British Thoracic Society. NEBUSAL is indicated to help increase the mobilisation of secretions in the lower respiratory tract in patients with persistent mucus due to its osmotic effects (for example, patients with cystic fibrosis or non-cystic fibrosis bronchiectasis).

How is it taken?

NEBUSAL comes in 4-ml vials that are compatible with any commonly used nebuliser. Nebulisers convert medical solutions into small aerosol droplets that can be directly inhaled from the mouthpiece of the device into the lungs and airways. In some patients, nebulised hypertonic saline solutions can result in bronchoconstriction. In these cases a bronchodilator may be used before NEBUSAL treatment. Always read the label.

Where can I learn more?

Click here for information on how to use Nebusal.

DELURSAN®
Close

DELURSAN® (ursodeoxycholic acid)
Tablets

DELURSAN® is available in the following European countries:

Patient Information Leaflet DELURSAN 250 mg, Tablets (English)
Patient Information Leaflet DELURSAN 500 mg, Tablets (English)
Advice of the French Transparency Commission DELURSAN 250 mg, Tablets (French)
Advice of the French Transparency Commission DELURSAN 500 mg, Tablets (French)

Aptalis is a wholly-owned subsidiary of Forest Laboratories, Inc.

FLUTTER®
Close

FLUTTER®
Mucus clearance device

FLUTTER® is available in the following European countries:



Aptalis is a wholly-owned subsidiary of Forest Laboratories, Inc.

LACTEOL®
Close

LACTEOL® Inactivated Lactobacillus LB*, Fermented culture medium (neutralized)**
Capsules and Powder for Oral Suspension in Sachet

* Lactobacillus fermentum and Lactobacillus delbrueckii
** Composition of the culture medium: lactose monohydrate, casein peptone, yeast extract, sodium acetate trihydrate, dipotassium phosphate, purified water.

LACTEOL® is available in the following European countries:

Summary of Product Characteristics LACTEOL 170 mg, Capsules (English)
Patient Information Leaflet LACTEOL 170 mg, Capsules (English)
Patient Information Leaflet LACTEOL 340 mg, Capsules (English)
Patient Information Leaflet LACTEOL 340 mg, Powder for Oral Suspension in Sachet (English)
Advice of the French Transparency Commission (French)

Aptalis is a wholly-owned subsidiary of Forest Laboratories, Inc.

PANZYTRAT®
Close

PANZYTRAT® (Pancreatin)
Capsules with microtablets

PANZYTRAT® is available in the following European countries:



Aptalis is a wholly-owned subsidiary of Forest Laboratories, Inc.

PYLERA®
Close

PYLERA® (Bismuth Subcitrate Potassium, Metronidazole, Tetracycline HCl)
Capsules

PYLERA® is available in the following European countries:

Approval is pending in other European countries.

Learn more about PYLERA® at PYLERA.COM

Aptalis is a wholly-owned subsidiary of Forest Laboratories, Inc.

TRANSULOSE®
Close

TRANSULOSE® (Lactulose / Mineral oil)
Oral Jelly in Jars and Oral Paste in Sachets

TRANSULOSE® is available in the following European countries:

Summary of Product Characteristics TRANSULOSE 100 g, Oral Jelly in Jars (French)
Summary of Product Characteristics TRANSULOSE 100 g, Oral Jelly in Jars (English)
Patient Information Leaflet TRANSULOSE 100 g, Oral Jelly in Jars (French)
Patient Information Leaflet TRANSULOSE 100 g, Oral Jelly in Jars (English)
Summary of Product Characteristics TRANSULOSE 5 g, Oral Paste in Sachets (French)
Summary of Product Characteristics TRANSULOSE 5 g, Oral Paste in Sachets (English)
Patient Information Leaflet TRANSULOSE 5 g, Oral Paste in Sachets (French)
Patient Information Leaflet TRANSULOSE 5 g, Oral Paste in Sachets (English)
Summary of Product Characteristics TRANSULOSE 10 g, Oral Paste in Sachets (French)
Summary of Product Characteristics TRANSULOSE 10 g, Oral Paste in Sachets (English)
Patient Information Leaflet TRANSULOSE 10 g, Oral Paste in Sachets (French)
Patient Information Leaflet TRANSULOSE 10 g, Oral Paste in Sachets (English)
Advice of the French Transparency Commission (French)

Aptalis is a wholly-owned subsidiary of Forest Laboratories, Inc.

VIATOL®
Close

VIATOL® (Glucose, Sodium Chloride and Potassium)
Powder for Oral Solution

VIATOL® is available in the following European countries:

Summary of Product Characteristics VIATOL, Powder for Oral Solution (French)
Advice of the French Transparency Commission (French)

Aptalis is a wholly-owned subsidiary of Forest Laboratories, Inc.